Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO 140 (leronlimab) monotherapy extension in virologically suppressed HIV-1 patients
NCT05271370Phase 3Terminated
- Sponsor
- CytoDyn Inc.
- Start
- Aug 2017
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of leronlimab in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by CytoDyn Inc. Primary endpoints: Adverse Events at 197 weeks and Virologic Failure at 197 weeks. Started Aug 2017; status: terminated.
02
Drugs
leronlimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05271370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271370.